학술논문
Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial
Document Type
Article
Author
Batmunkh, Tsetsegsaikhan; Moore, Kerryn A.; Thomson, Helen; Altangerel, Bolor; Amraa, Otgonjargal; Avaa, Naranbaatar; Batbayar, Lkhagvagaram; Batsukh, Khishigjargal; Bright, Kathryn; Burentogtokh, Tsogjargal; Ha Do, Lien Anh; Dorj, Gantuya; Hart, John D.; Javkhlantugs, Khulan; Jigjidsuren, Sarantsetseg; Justice, Frances; Li, Shuo; Licciardi, Paul V.; Mashbaatar, Khaliunaa; Mazarakis, Nadia; Neal, Eleanor F.G.; Nguyen, Cattram Duong; Ochirbat, Batbayar; Tsolmon, Bilegtsaikhan; Tuya, Alimaa; Surenjav, Unursaikhan; von Mollendorf, Claire; Mulholland, Kim
Source
In The Lancet Regional Health - Western Pacific January 2024 42
Subject
Language
ISSN
2666-6065